Earlier reports have suggested that the BCR/ABL oncogene, associated with chronic myeloid leukemia, induces a mutator phenotype; however, it is unclear whether this leads to long-term changes in ...
Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib. Background: The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic ...
Leukemia is an umbrella term for multiple different cancers that form in the blood, one such member of the leukemia family being chronic myelogenous leukemia (CML). CML is caused by a chromosomal ...
The chromosomal translocation [t (9;22)] associated oncogenic fusion protein BCR-ABL drives 90% of chronic myelogenous leukemia (CML). Approximately 9,000 CML diagnosis are expected for 2023. While ...
Human chronic myelogenous leukemia (CML) and a subset of acute lymphocytic leukemia (ALL) are caused by expression of Bcr-Abl, a fusion gene generated by reciprocal t(9;22)(q34;q11) chromosome ...
The Ph translocation found in CML results in the juxtaposition of a portion of the human homologue of the Abelson murine leukemia (ABL) gene from chromosome 9 and the breakpoint cluster region (BCR) ...
Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). A phase II study with ...
Chronic myeloid leukemia (CML) is a rare blood cancer that develops in the bone marrow. Karyotyping is a genetic technique doctors use to diagnose CML and choose more effective treatments. Karyotyping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results